January 30, 2023
Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder,
January 25, 2023
2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug
January 18, 2023
Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would
January 10, 2023
On Friday, atai Life Sciences shared results from its Phase IIa trial with PCN-101, R-ketamine, for treatment-resistant depression. Disappointingly, the
January 4, 2023
The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews
December 28, 2022
In the final quarter of 2022, Beckley Psytech shared updates on its drug development pipeline and reported the acquisition of
December 14, 2022
Despite a challenging economic climate in the latter half of 2022, the year was marked by major milestones in psychedelic
December 7, 2022
UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows
November 30, 2022
On Tuesday, 29 November, PSYCH released the fourth edition of The Psychedelics as Medicine Report. The report, expanded to include
November 23, 2022
Veteran affairs receive bipartisan support across North America, with public opinion prompting lawmakers and regulators to support innovations in veteran
November 15, 2022
Tomorrow, Thursday, 17 November, industry leaders will meet in London for Emerging Innovations in Psychedelic Healthcare, to evaluate milestones in
November 7, 2022
Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Policy Reform Group (CDPRG) representative, Crispin Blunt
